Claims for Patent: 4,931,288

Summary for Patent: 4,931,288

Title:	Controlled release compositions (II)
Abstract:	A controlled release composition comprising a prostaglandin and a polymeric carrier therefor comprising residues having a ratio of number average molecular weight to functionality greater than 1,000 which comprise polyethylene oxide and are cross-linked through urethane groups.
Inventor(s):	Embrey; Mostyn (Oxford, GB2), Graham; Neil B. (Dunbartonshire, GB6)
Assignee:	Lloyds Bank PLC (GB)
Application Number:	07/188,674
Patent Claims:	1. A controlled release composition comprising a prostaglandin and a polymeric carrier therefor comprising residues which are cross-linked through urethane groups, or analogues thereof, and which comprise polyethylene oxide having a ratio of number average molecular weight to functionality greater than 1,500, the degree of cross-linking being such that there is at least one cross-linking point per ten residues comprising the said polyethylene oxide but such that the proportion of the said polyethylene oxide is greater than 50% by weight of the polymeric carrier which, when prostaglandin-free, is a hydrogel in the dry form at 20.degree. C., contains crystalline regions, and exhibits syneresis in the wet form. 2. A controlled release composition comprising a prostaglandin and a polymeric carrier therefor comprising residues which are cross-linked through urethane groups, or analogues thereof, and which comprise polyethylene oxide having a ratio of number average molecular weight to functionality greater than 1,500, the degree of cross-linking being such that there is at least one cross-linking point per ten residues comprising the said polyethylene oxide but such that the proportion of the said polyethylene oxide is greater than 50% by weight of the polymeric carrier which, in the presence of said prostaglandin, is a hydrogel in the dry form at 20.degree. C., contains crystalline regions, and exhibits syneresis in the wet form. 3. The controlled release composition of claim 1, further comprising an additional drug other than a prostaglandin. 4. The controlled release composition of claim 2, further comprising an additional drug other than a prostaglandin. 5. The composition according to claim 1, wherein the polyethylene oxide has a ratio of number average molecular weight to functionality greater than 2,000. 6. The composition according to claim 1, wherein the polyethylene oxide is the reaction product of a mixture comprising (i) an aliphatic or aromatic compound which is di-, tri- or tetra-substituted by at least one hydroxyl, carboxyl, amino or mercapto group with (ii) ethylene oxide. 7. The composition according to claim 6 wherein component (i) comprises a di- or tri-hydroxyl-substituted aliphatic compound. 8. The composition according to claim 1, wherein the degree of cross-linking of the polymeric carrier is such that there is at least one cross-linking point per five residues comprising the said polyethylene oxide. 9. The composition according to claim 1, wherein the degree of cross-linking of the polymeric carrier is such that there is at least one cross-linking point per residue comprising the said polyethylene oxide. 10. The composition according to claim 1, wherein the degree of cross-linking of the polymeric carrier is such that the proportion of the said polyethylene oxide is greater than 70% by weight of the polymeric carrier. 11. The composition according to claim 1, wherein the degree of cross-linking of the polymeric carrier is such that the proportion of the same polyethylene oxide is greater than 80% by weight of the polymeric carrier. 12. The composition according to claim 1, wherein the polymeric carrier comprises up to 20% by weight of an additional polyalkylene oxide. 13. The composition according to claim 1, wherein the polymeric carrier comprises up to 20% by weight of an additional polyethylene oxide having a ratio of number average molecular weight to functionality not greater than 1000. 14. The composition according to claim 1, wherein the polymeric carrier comprising up to 30% of its weight of a water-extractable fraction. 15. The composition according to claim 1, wherein the amount of water-extractable fraction has been reduced to no more than 5% of the polymeric carrier. 16. The composition according to claim 1, wherein the prostaglandin is a naturally-occurring prostaglandin of the E and F.sub..alpha. groups. 17. The composition according to claim 16, wherein the prostaglandin is PGE.sub.2 or PGF.sub.2.alpha.. 18. The composition according to claim 1, wherein the prostaglandin is a synthetic analogue. 19. The composition according to claim 18, wherein the prostaglandin is 15-methyl-PGF.sub.2.alpha., 16,16-dimethyl-PGE.sub.2, 16,16-dimethyl-PGE.sub.2 parabenzaldehyde semicarbazone ester, 16-phenoxy-17,18,19,20-tetranor-PGE.sub.2, 16,16-dimethyl-trans .DELTA..sup.2 -PGE.sub.1, its methyl ester or 16-(3-trifluoromethylphenoxy)-17,18,19,20-tetranor-PGF.sub.2.alpha.. 20. The composition according to claim 1, in the shape of a cylinder, film or slab. 21. The composition according to claim 20, wherein the cylinder is hollow or the film or slab has at least one hole or hollow therein to modify the release properties. 22. The composition according to claim 1, for use as an abortifacient. 23. The composition according to claim 1, for use in the induction of labor. 24. The composition according to claim 1, for use as a contraceptive. 25. The composition according to claim 1 for use in the treatment of schizophrenia. 26. The composition according to claim 1, for use in the treatment of cervical imcompetence in livestock.